Standard BioTools Inc. (LAB)

Market Cap	239.47M -47.3%
Revenue (ttm)	84.60M -4.8%
Net Income	84.91M
EPS	0.22
Shares Out	392.58M
PE Ratio	2.78
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,002,539
Open	0.6221
Previous Close	0.6200
Day's Range	0.6000 - 0.6248
52-Week Range	0.5881 - 1.7200
Beta	1.35
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 13, 2026

About LAB

Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through Proteomics and Genomics segments. Its proteomics and genomics include instruments, consumables, and assays for clinical and diagnostic uses. The company also provides SomaScan platform that enables researchers to measure proteins simultaneo...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Feb 10, 2011
• Employees: 389
• Stock Exchange: Nasdaq
• Ticker Symbol: LAB
• Website: https://www.standardbio.com

Financial Performance

In 2025, Standard BioTools's revenue was $85.33 million, a decrease of -6.24% compared to the previous year's $91.01 million. Losses were -$74.90 million, -59.49% less than in 2024.

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Oct 31, 2026

Data Sources Report a data error